Short answer: there is no published evidence that CJC-1295 raises testosterone, lowers it, or otherwise acts directly on the testosterone axis. CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue. It acts on pituitary cells that make growth hormone, which belongs to a different hormonal axis from the one that controls testosterone. The published CJC-1295 trials report growth hormone and IGF-I as their main outcomes. Whether the two axes influence one another is a genuine endocrine question, but for this molecule it has not been answered in the papers we can cite. This guide separates the two systems, explains where they overlap, and says what is unknown. It is a research summary, not performance or use advice.
Two axes that are often confused
Searches such as “does CJC-1295 impact testosterone” and “does CJC mess with testosterone” come from a reasonable intuition: hormones interact, and a compound that changes one hormone might change another. The intuition is right in general, and the answer to the specific question depends on which axis each compound acts on.
The growth hormone axis. The hypothalamus releases GHRH. GHRH acts on the GHRH receptor on somatotroph cells in the anterior pituitary, which release growth hormone (GH). GH acts on the liver and other tissues to produce IGF-I, which feeds back to the hypothalamus and pituitary. CJC-1295 is a modified GHRH analogue designed to act at that first receptor.
The reproductive (HPG) axis. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses. GnRH acts on gonadotroph cells in the pituitary, which release luteinising hormone (LH) and follicle-stimulating hormone (FSH). In males, LH acts on Leydig cells in the testis to make testosterone, which feeds back to the hypothalamus and pituitary.
The two axes share a hypothalamus and a pituitary, but they use different releasing hormones, different receptors and different pituitary cell types. A GHRH analogue has no obvious reason to act at a GnRH receptor, and nothing in its design suggests it would. If you are new to the analogue itself, our complete CJC-1295 research guide explains its structure.
What the CJC-1295 trials actually measured
Three papers describe the core pharmacology.
- Jetté et al. (Endocrinology, 2005) described GRF(1-29) bioconjugates with albumin and showed that they activate the GRF receptor on anterior pituitary cells in vitro. This is the foundation for the “drug affinity complex” (DAC) design.
- Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) reported two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults. The main outcome measures were peak concentrations and area under the curve of GH and IGF-I, plus pharmacokinetic parameters for CJC-1295. The authors reported dose-dependent increases in mean GH (2- to 10-fold for six days or more) and IGF-I (1.5- to 3-fold for 9–11 days), an estimated half-life of 5.8 to 8.1 days, and no serious adverse reactions.
- Ionescu and Frohman (Journal of Clinical Endocrinology and Metabolism, 2006) reported that pulsatile GH secretion persisted during continuous stimulation by CJC-1295, which is important for understanding the physiology of a long-acting analogue.
Notice what the abstract of the main clinical paper lists as outcomes: GH, IGF-I and pharmacokinetics. Testosterone is not among the main outcome measures in that abstract. That is not proof that nothing happened to testosterone. It means these papers do not report it as an outcome in the abstracts, so they cannot be used to support a claim in either direction.
Where the two axes do interact
It would be misleading to leave the impression that the axes are sealed off from each other. Endocrine physiology describes several points of contact.
- IGF-I and gonadal tissue. IGF-I receptors are present on cells of the gonads, and the literature describes IGF-I as modulating the responsiveness of gonadal cells to gonadotropins. This is the biology discussed in our article on ipamorelin and reproductive hormone research.
- Shared metabolic and stress inputs. Energy balance, body composition, sleep and stress influence both axes. A change in one can therefore coincide with a change in the other without one directly causing it.
- Other secretagogues. Some growth hormone secretagogues affect additional hormones, such as cortisol or prolactin, depending on the compound; the review by Sigalos and Pastuszak (Sexual Medicine Reviews, 2018) discusses the safety and efficacy of growth hormone secretagogues as a class. Such effects are compound-specific and cannot be assumed for another molecule.
These are reasons to design an experiment carefully. They are not evidence that CJC-1295 changes testosterone. For this molecule, any crosstalk is, on the evidence we can cite, an open question.
Why “does it affect testosterone” is hard to answer
Even in principle, a clean answer needs a study designed to ask it. That means measuring total and free testosterone, LH and FSH, SHBG and often oestradiol, at several time points that account for the pulsatile, diurnal pattern of the reproductive hormones. It means a placebo comparator, adequate numbers, and a population in which baseline levels are well characterised. It means controlling for time of day, sleep, body composition and acute stress. A paper that was designed to measure GH and IGF-I will usually not meet those requirements, which is a further reason why existing CJC-1295 trials cannot answer the testosterone question by implication.
Common misreadings
- “It raises GH, so it must raise testosterone.” The axes are separate, and a rise in one does not entail a rise in the other.
- “It is a peptide hormone, so it must act like a steroid hormone.” Chemical class and mechanism are different things.
- “Anecdotes show an effect.” Self-reports are subject to confounding by everything else that changes at the same time, and are not evidence about the molecule.
- “Absence of a testosterone result means no effect.” It means no published evidence either way.
Practical points for researchers
- State which analogue you mean. CJC-1295 with DAC and without DAC differ in half-life by days versus minutes, which affects experimental design; see our comparison of CJC-1295 with and without DAC.
- Design endocrine studies around pulsatility. Single time-point measurements of LH or testosterone are misleading.
- Verify material. Peptides Lab UK supplies CJC-1295 with DAC and CJC-1295 without DAC for laboratory research, with batch certificates; every batch is HPLC & COA Verified, which documents identity and purity.
- Do not infer clinical effects from a certificate. A certificate is not evidence of activity.
Reading reproductive hormone data
Reproductive hormones are awkward to measure, which is another reason casual claims about them deserve scepticism. In men, LH is released in pulses roughly every one to two hours, and testosterone follows a daily rhythm that peaks in the morning, so a single sample can fall almost anywhere on the curve. Total testosterone includes the fraction bound to sex hormone-binding globulin (SHBG) and to albumin, and free testosterone is the small remainder that is not bound; changes in SHBG can move total testosterone without any change in testis output. Immunoassays and mass-spectrometry methods can also give different numbers, especially at low concentrations. A credible study therefore reports the assay, the time of sampling, fasting status and the handling of SHBG, and it includes repeated measures. When a claim about “testosterone” cites a single reading with none of these details, it should be treated as an anecdote, whichever direction it points.
What a rigorous study of this question would look like
If a laboratory or clinical group did want to answer the testosterone question for a GHRH analogue, a sensible design would be a randomised, placebo-controlled study with a pre-registered primary endpoint, a sample size calculated for the expected variability of the hormone, and multiple blood draws across several days rather than one. It would measure LH, FSH, total and free testosterone, SHBG and oestradiol with the same assay each time, record sleep and body composition, and analyse the data with the pulsatile pattern in mind. It would also report negative findings. The absence of that study is not a gap that marketing copy should fill with confident language in either direction. It is simply the current state of the evidence, and a reader who knows what a good answer would require is well placed to spot a poor one.
Frequently asked questions
If you are weighing UK peptides suppliers, our guide to buying peptides in the UK and the best research peptides UK scorecard explain what documentation to look for.
Does CJC-1295 impact testosterone?
There is no published evidence that it does, directly or indirectly, in the papers we can cite. CJC-1295 is a GHRH analogue acting on pituitary somatotrophs; the published trials report GH and IGF-I as their main outcomes, not testosterone.
Does CJC mess with testosterone?
No study we can cite shows that. The growth hormone axis and the testosterone (HPG) axis use different releasing hormones, receptors and pituitary cell types, although they interact through factors such as IGF-I and metabolic state.
Is CJC-1295 the same as a steroid?
No. CJC-1295 is a peptide analogue of growth hormone-releasing hormone, not a four-ring steroid, and it does not act at the androgen receptor.
What did the CJC-1295 trials measure?
The Teichman trials in healthy adults measured GH and IGF-I and CJC-1295 pharmacokinetics, reporting dose-dependent increases in both hormones and a half-life of 5.8 to 8.1 days. Testosterone was not a main outcome in the abstract.
Why can’t existing studies answer the testosterone question?
A proper answer needs a study designed to measure testosterone, LH, FSH and related hormones across time points that account for pulsatile and diurnal rhythms, with a placebo comparator. The CJC-1295 trials were designed around GH and IGF-I.
Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article is educational and is not medical advice or performance advice.